Persistent Nonvalvular Atrial Fibrillation — Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
Citation(s)
An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation